Business
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented
About this update from Biodesix, Inc.
[{"type":"text","content":" BOULDER, Colo.--(BUSINESS WIRE)--\nBiodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules. The posters, presented May 8-9, 2023, highlighted potential cost savings in both Medicare and commercially insured patient populations with use of the tests.\n\n\nThe analyses estimated cost savings in a hypothetical population of 1 million patients in a US Medicare or commercial payer setting over a 2-year time horizon. The results predicted that plans would save $600,000 to $3.9 million with use of the tests in the treatment pathways for managing pulmonary nodules.\n\n\nThe two posters assessing budget impact of the Nodify XL2 test, titled “Budget Impact of a Blood-Based Integrated Classifier Test to Reclassify Risk of Pulmonary Nodules in a US Commercial Payer Setting” and “Budget Impact of a Blood-Based Integrated Classifier Test to Down Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting,” highlighted the cost-savings to payers by incorporating Nodify XL2 use, with cost-savings largely attributed to the ability of the test to reduce invasive procedures on benign nodules. Prior studies have shown that work up of benign nodules make up the majority of costs of pulmonary nodule management.\n\n\nThe two posters assessing budget impact of the Nodify CDT test, titled \"Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Commercial Payer Setting\" and \"Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting,\" focused on the ability of the test to support earlier diagnosis of lung cancer leading to an increase in stage I diagnoses and improved patient outcomes. At earlier stages, patients are eligible for potentially curative surgical resection with a lower cost profile compared to standard of care therapies for advanced stage lung cancer.\n\n\n\"These data presented at ISPOR solidifies the transformative potential of our Nodify CDT and Nodify XL2 tests,\" said Scott Hutton, CEO of...